Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

C2 PHARMA Expands Advisory Board To Support Growth Objectives

   by White Matter Communications, Contributor    148    Comments 0

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Luxembourg, March 3, 2020C2 PHARMA s.a.r.l. (C2P), a Luxembourg-based phytochemical and chemical pharmaceutical manufacturing and distribution group, has expanded their advisory board with a new member. Consisting of well-respected pharmaceutical industry experts, the board provides strategic guidance on the progress and growth of the company via organic and M&A activities in the mid and long-term.

 

“The C2 PHARMA advisory board now includes Jim Miller, who joins existing members Dr. Uwe H. Böhlke, Joachim Roeser, and Dr. Jürgen Sackhoff,” Andrew Badrot, CEO of C2 PHARMA said. “We are thrilled to expand our advisory board and align to gain their insight as we grow into a premier ophthalmic and niche active pharmaceutical ingredient (API) supplier with a unique virtual manufacturing model. The prowess each member brings to the board is invaluable in creating sustainable growth, while making a clear mark on this industry.”

Jim Miller founded PharmSource, a pioneering online database for contract manufacturing intelligence now run by Global Data. He is regarded as a biopharmaceutical contract manufacturing and development sector expert and is a frequent contributor to industry publications and events, as well as working as a consultant and a member of the Board of Advisors of C2 PHARMA.

Dr. Uwe H. Böhlke is a leading executive manager and board member for companies across the chemicals, pharmaceuticals and polymers industries. Today, he is the chief operating officer (COO) at REHAU. A former member of the executive board at Lonza, and Oerlikon Surface Solutions AG, since 2014 he has been a member of the Board of Advisors of C2 PHARMA.

Joachim Roeser has vast experience in business development and executive management for the chemicals, material science and polymers industries. Formerly, he held CEO and president positions for Amber Chemical Group, Luzenac and Ferro Group. Today he is the board director for Innospec Inc., in addition to his role as a member of the Board of Advisors of C2 PHARMA.

Dr. Jürgen Sackhoff is a distinguished professional with a diverse executive and legal background. He spent more than 3 years as CEO at SGD Pharma, with a history of 14 years at Schott AG ending as Executive Vice President of Pharmaceutical Systems, and nearly a decade of General Counsel and legal work with Henkel Corporation and Generali. In 2018, he branched into independent executive consultation, legal and board work, including joining as a member of the Board of Advisors of C2 PHARMA.

The announcement follows a recent expansion of the company’s API product portfolio with successful validation of Homatropine Hydrobromide and additions to the Digoxin API offering. Further R&D development and tech transfers are in process and will be announced in 2020.

Share this:              

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *